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Context: Thyroid hormones influence kidney function and thereby might alter serum urate 
levels, a major risk factor for gouty arthritis.
Objective: To assess the risk of developing incident gout in association with hypothyroidism 
or hyperthyroidism.
Design: Retrospective population-based case–control analysis..
Setting: UK-based Clinical Practice Research Datalink, a primary care research database.
Patients: We identified adult patients with a diagnosis of incident gout between 1990 and 2014. 
We matched one control to each gout case in terms of age, sex, general practice, calendar time, 
and years of active history in the database.
Main outcome measure: We used conditional logistic regression to calculate odds ratios 
(ORs) with 95% confidence intervals (CIs) for developing gout in association with hypo- or 
hyperthyroidism and adjusted for potential confounders.
Results: The study population encompassed 68,159 incident gout cases, of whom 78.8% 
were male, and the same number of matched controls. There was no increased risk of gout in 
patients with hypothyroidism: adjusted OR of gout of 1.12 (95% CI 1.05–1.20) compared with 
no hypothyroidism. Current short-term treatment of thyroid hormone replacement therapy was 
associated with an adjusted OR of gout of 1.54 (95% CI 1.24–1.92), compared with no treatment. 
Neither hyperthyroidism nor current treatment with thyroid suppression therapy was associated 
with gout (adjusted OR, 1.08 [95% CI 0.95–1.22] and 0.82 [95% CI 0.57–1.17], respectively).
Conclusion: This large observational study does not provide evidence that hypothyroidism or 
hyperthyroidism, irrespective of treatment, is associated with a clinically relevant increased risk 
of developing incident gout. There may be an exception among patients with newly diagnosed 
and treated hypothyroidism.
Keywords: hypothyroidism, hyperthyroidism, Clinical Practice Research Datalink, epidemiology
Introduction
Gout is a painful rheumatic disease characterized by deposition of uric acid crystals 
in the joints and elevation of serum uric acid levels, leading to acute inflammatory 
arthritis.1,2 The estimated prevalence of gout in the UK population is 1.4%,3,4 with 
increasing prevalence in older age groups and with a male-to-female ratio of 3.6–1.3 
Various reasons for the difference between males and females in the etiology of the 
disease have been postulated.5,6 
Several case series provided evidence of a possible association between hypothy-
roidism and gout.7–9 One study reported a material association between hypo- and 
hyperthyroidism and the risk of gout,10 and two other studies reported a correlation 
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between thyroid disorders and hyperuricemia, an important 
risk factor for the development of gout.11,12 The association 
between hypothyroidism and hyperuricemia has been firmly 
established, whereas the relationship between hyperthyroid-
ism and hyperuricemia remains controversial.11 A possible 
explanation is that thyroid hormones influence serum urate 
levels by regulation of glomerular filtration rate (GFR).13 The 
effects of thyroid hormones on kidney function are the result 
of direct renal effects, as well as of metabolic and cardiovas-
cular effects.13 Hypothyroidism decreases and hyperthyroid-
ism increases GFR, resulting in increased serum urate levels 
in patients with hypothyroidism and in decreased serum urate 
levels in patients with hyperthyroidism.13 However, a previ-
ous small study showed that hyperthyroidism can cause a 
significant increase in serum uric acid, although less so than 
hypothyroidism.11 Furthermore, one study reported a weak 
association between thyroid stimulating hormone (TSH) and 
serum uric acid levels.14 
Although the association between hypo- and hyper-
thyroidism and kidney function has been described in the 
literature, the risk of clinically manifest gout in association 
with hypo- or hyperthyroidism has not been comprehensively 
examined. Additionally, the association between use of thy-
roid hormone replacement or suppression therapy and gout 
has not yet been studied. We therefore assessed the risk of 
developing incident gout in association with hypo- or hyper-
thyroidism and thyroid hormone replacement or suppression 
therapy, respectively.
Patients and methods
Data source
We derived data from the UK-based Clinical Practice 
Research Datalink (CPRD), a large primary care database 
that was established in 1987, encompassing data from ~600 
general practices and 10 million patient records. Enrolled 
patients are representative of the UK population regarding 
age, sex, and ethnicity.13 The CPRD contains information on 
patient demographics and characteristics, lifestyle variables, 
such as medical diagnoses, prescriptions, body mass index 
(BMI), smoking status, and alcohol consumption, symptoms, 
referrals to consultants, and hospitalizations. The general 
practitioners generate drug prescriptions directly from the 
computer, using a coded drug dictionary.15 The CPRD has 
been described in detail elsewhere16,17 and has been validated 
extensively.18–22 It has been the source of numerous epidemio-
logical studies published in peer-reviewed journals, including 
research on gout.3,23–28 
This study has been approved by the Independent Scien-
tific Advisory Committee for the Medicines and Healthcare 
Products Regulatory Agency database research (protocol 
number 15_079R). The committee did not require written 
informed consent be obtained from the participants, as this 
was a retrospective study, and all data was anonymized.
Study population
Case patients
Based on Read codes, we identified patients in the CPRD 
aged ≥18 years who had a first-time diagnosis of gout 
recorded between 1990 and 2014. The date of the first 
diagnosis of gout was referred to as the “index date”. We 
excluded all cases with <3 years of recorded history prior to 
the index date to reduce the likelihood of including prevalent 
gout cases. We further excluded all patients with a diagnosis 
of HIV or cancer (except nonmelanoma skin cancer) prior to 
the index date, as well as those with a differential diagnosis 
of gout such as hemochromatosis, septic arthritis, rheumatoid 
arthritis, or osteoarthritis at any time within their patient 
record. We did this to reduce the risk of misclassification, 
i.e., including alleged gout patients who in fact had another 
disease with similar symptoms. The diagnosis of gout in the 
CPRD has been validated in a previous study by review of 
medical records of incident gout.27 They determined gout 
patients with an incident diagnosis of gout without elevated 
urate level or treatment against elevated urate levels as we 
used it as probable cases.27 However, the comparison of prob-
able and confirmed cases resulted in similar results.27 Similar 
case definitions to ours have been used by several authors in 
previous studies.3,23–26,28 
Control patients
We identified at random from the CPRD a control group of 
patients without any Read code for gout at any time within 
the patient’s record. They were matched 1:1 to cases on age, 
sex, general practice, number of years of previous recorded 
history in the database, and calendar time (by assigning the 
index date of the case to his or her control). We applied the 
same exclusion criteria to controls as to cases.
Definition and classification of thyroid 
disorders and their therapy
We assessed whether cases and controls had a recorded 
Read-coded diagnosis of hypo- or hyperthyroidism prior 
to the index date. We further assessed drugs used to treat 
hypothyroidism (thyroid hormone replacement therapy, i.e., 
levothyroxine) or hyperthyroidism (thyroid hormone sup-
pression therapy, i.e., carbimazole) by identifying prescrip-
tions prior to the index date. We classified exposed patients 
into “current users” (last prescription recorded <180 days 
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prior to the index date) and “past users” (last prescription 
recorded ≥180 days prior to the index date). We determined 
a cutoff of 180 days for current use since these substances 
are prescribed for long-term use, and 90 days is the typical 
maximal length of a prescription in the UK. We further clas-
sified users according to duration of use, defining the number 
of prescriptions (1–9, 10–19, 20–29, and ≥30 prescriptions) 
prior to the index date as proxy for treatment duration.
Covariates
Covariates in this study included BMI, categorized as (12.0–
18.4, 18.5–24.9, 25.0–29.9, 30.0–59.0 kg/m2, or unknown), 
smoking status (nonsmoker, current smoker, ex-smoker, or 
unknown), and alcohol consumption (never, current [1–9 
units per week; 10–19 units per week; ≥20 units per week], 
past, or unknown). We assessed whether cases and controls 
had a record (yes/no) of hypertension, diabetes mellitus, 
dyslipidemia, renal impairment, congestive heart failure, 
ischemic heart disease, or transient ischemic attack/stroke at 
any time prior to the index date. We assessed renal impair-
ment by calculating the estimated GFR (eGFR) at or closest 
prior to the index date. We classified patients as having renal 
impairment if they had at least two increased measurements 
of serum creatinine that were ≥90 days apart, resulting in two 
eGFR estimates of <90 mL/min, or a Read code of chronic 
kidney disease (CKD), at any time prior to the index date. We 
used the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation to calculate the eGFR.29,30 We further 
assessed ever versus never use of antihypertensive drugs such 
as angiotensin-converting enzyme inhibitors, angiotensin 
receptor blockers, diuretics (including thiazide diuretics, loop 
diuretics, and potassium-sparing diuretics), beta-blockers, 
calcium channel blockers, and nitrates as well as use of statins 
prior to the index date. Furthermore, we assessed the closest 
values of eGFR (no value, <30 mL/min, 30–60 mL/min, or 
60–90 mL/min) recorded prior to the index date.
Statistical analysis
We conducted multivariate conditional logistic regression 
analyses to compare the exposure prevalence of hypo- or 
hyperthyroidism and thyroid hormone replacement or sup-
pression therapy between cases and controls. We further 
stratified our analyses by thyroid hormone therapy (defined 
as the number of prescriptions of thyroid drugs prior to the 
index date), to assess potential effect modification by thyroid 
disease duration. We presented relative risk estimates as odds 
ratios (ORs) with 95% confidence intervals (CIs) and consid-
ered a two-sided p-value of <0.05 statistically significant. We 
conducted the statistical analysis using the software program 
SAS, Version 9.4 (SAS institute, Inc., Cary, NC, USA).
We adjusted our analyses for patient characteristics, 
comorbidities, or concomitant drug use in the multivariate 
analysis if these variables were predictor variables for gout 
known a priori from the literature.3 In all analyses, these 
were BMI, smoking status, and alcohol consumption. We 
additionally adjusted the analyses for lifestyle factors (alcohol 
consumption and smoking status) and concomitant diseases 
such as hypertension, congestive heart failure, ischemic 
heart disease, and renal impairment. We adjusted analyses 
for comedication use of diuretics, all other antihypertensive 
drugs assessed (including nitrates), and statins, recorded at 
any time prior to the index date.
Sensitivity analyses
In a first sensitivity analysis, we excluded patients with a 
history of renal impairment, congestive heart failure, or 
hypertension prior to the index date. In a second sensitivity 
analysis, we stratified the study population by the presence 
or absence of these comorbidities. In a third sensitivity 
analysis, we conducted the analysis in a subset of cases and 
their matched controls that were treated with nonsteroidal 
antiinflammatory drugs, colchicine, and/or corticosteroids 
within 7 days or with uricosuric/uricostatic drugs within 
90 days prior to or after the index date. In a fourth sensitivity 
analysis, we restricted the study population to patients with 
incident thyroid disorders or use of thyroid therapy (patients 
with no diagnosis of thyroid disorder and no use of thyroid 
therapy within the first year of their registered history) to 
address potential prevalent user bias. In a fifth sensitivity 
analysis, we restricted the analysis to cases who were treated 
with thyroid hormone suppression therapy or nonpharmaco-
logical treatment only (i.e., surgical removal of parts of the 
gland, radiotherapy, or pharmacological intervention) prior 
to the index date.
Stratified analyses and effect modification
In a first analysis, we stratified the study population by sex to 
assess potential effect modification by sex on the association 
between thyroid disorders and gout. In a second analysis, we 
assessed the association between thyroid disorders and gout 
stratified by eGFR level (no value recorded, <30 mL/min, 
30–60 mL/min, or 60–90 mL/min).
Results
The study population encompassed 68,159 incident adult 
gout cases and the same number of matched controls. A total 
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of 78.8% cases were male, resulting in a male-to-female 
ratio of 3.7 to 1. Mean age (± standard deviation) of cases 
was 58 ± 15.8 years, and female cases were older (65.9 ± 
15.6 years) than male cases (56.6 ± 15.0 years) at first gout 
diagnosis. Mean BMI at the closest general practitioner visit 
prior to the index date was 27.6 ± 5.1 kg/m2. Increasing BMI 
and increasing current alcohol consumption were associated 
with increasing ORs of gout. Further results are displayed 
in Table 1. Risk factors for gout that are known from the lit-
erature, such as hypertension, renal impairment, congestive 
heart failure, and ischemic heart disease,3 were all associated 
with an increased risk of incident gout in our study popula-
tion. Current use of most antihypertensive drugs, except 
calcium channel blockers and nitrates, was associated with 
an increased OR of gout compared with never use of these 
drugs. Further results are displayed in Table 2.
There was no overall association between diagnosis of 
hypothyroidism and risk of gout (adjusted [adj] OR 1.12, 
95% CI 1.05–1.20) nor was hyperthyroidism associated 
with development of gout (adj OR 1.08, 95% CI 0.95–1.22; 
Table 3). However, current short-term use of these drugs 
showed a tendency toward a small increase in risk: adj OR 1.54 
(95% CI 1.24–1.92) compared with nonuse. Thyroid hormone 
suppression therapy was not associated with gout. Further 
results are displayed in Table 4. In the analysis of treatment 
duration, tests for trend were statistically significant for cur-
rent short-term use (1–9 prescriptions prior to the index date) 
of thyroid hormone replacement therapy (data not shown).
Sensitivity analyses
There were no material differences from the main analysis in 
any of the five sensitivity analyses (Tables S1–S3).
Table 1 Demographics and characteristics of patients with gout and matched control patients
Variable Cases, n (%),  
N=68,159
Controls, n (%),  
N=68,159
OR crude (95% CI) OR adj* (95% CI)
Sex°
Male 53,736 (78.8) 53,736 (78.8) NA NA
Female 14,423 (21.2) 14,423 (21.2) NA NA
Age group (years)°
<29 1,865 (2.7) 1,860 (2.7) NA NA
30–39 6,570 (9.6) 6,580 (9.7) NA NA
40–49 12,585 (18.5) 12,580 (18.5) NA NA
50–59 14,464 (21.2) 14,447 (21.2) NA NA
60–69 14,051 (20.6) 14,084 (20.7) NA NA
70–79 12,034 (17.7) 12,044 (17.7) NA NA
≥80 6,590 (9.7) 6,564 (9.6) NA NA
Body mass index category (kg/m2)
12.0–18.4 329 (0.5) 872 (1.3) 0.58 (0.51–0.66) 0.67 (0.58–0.77)
18.5–24.9 12,731 (18.7) 20,633 (30.3) 1 (Reference) 1 (Reference)
25.0–29.9 24,778 (36.4) 21,573 (31.7) 1.92 (1.86–1.98) 1.74 (1.68–1.79)
30.0–59.9 19,298 (28.3) 9,962 (14.6) 3.32 (3.21–3.44) 2.76 (2.66–2.87)
Unknown 11,023 (16.2) 15,119 (22.2) 1.10 (1.06–1.14) 1.46 (1.39–1.52)
Smoking status
Nonsmoker 29,426 (43.2) 28,601 (42.0) 1 (Reference) 1 (Reference)
Current smoker 10,703 (15.7) 13,899 (20.4) 0.74 (0.71–0.76) 0.75 (0.72–0.77)
Ex-smoker 23,135 (33.9) 18,126 (26.6) 1.31 (1.28–1.35) 1.08 (1.05–1.11)
Unknown 4,895 (7.2) 7,533 (11.1) 0.56 (0.53–0.58) 0.78 (0.74–0.83)
Alcohol consumption (units/week)§
Never/ex 8,143 (12.0) 9,616 (14.1) 1 (Reference) 1 (Reference)
Current unknown 14,278 (21.0) 14,754 (21.7) 1.16 (1.11–1.21) 1.21 (1.16–1.27)
Current 1–9 14,244 (20.9) 16,576 (24.3) 1.08 (1.04–1.12) 1.15 (1.10–1.20)
Current 10–19 9,768 (14.3) 8,090 (11.9) 1.57 (1.50–1.64) 1.72 (1.63–1.80)
Current >20 14,291 (21.0) 7,807 (11.5) 2.44 (2.33–2.55) 2.79 (2.65–2.93)
Unknown 7,435 (10.9) 11,316 (16.6) 0.76 (0.72–0.79) 1.07 (1.02–1.13)
General practitioner visits last year
0–2 9,614 (14.1) 18,923 (27.8)
3–4 5,230 (7.7) 6,064 (8.9) 0.28 (0.27–0.29) 0.47 (0.45–0.49)
5–9 10,840 (15.9) 10,598 (15.6) 0.50 (0.48–0.53) 0.77 (0.73–0.81)
≥10 42,475 (62.3) 32,574 (47.8) 0.64 (0.62–0.67) 0.88 (0.85–0.92)
Notes: °Matching variables: age, sex, general practice, history on the database, and index date. §1 U = 10 mL of pure ethanol (8 g of ethanol). *Adjusted for body mass index 
category, smoking status, alcohol consumption, hypertension, renal impairment, congestive heart failure, and ischemic heart disease/myocardial infarction.
Abbreviations: adj, adjusted; CI, confidence interval; NA, not applicable; OR, odds ratio.
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Stratified analyses and effect modification
There were no material differences from the main analysis 
when stratified by sex (Table S4). In patients who had an 
impaired eGFR at the closest general practitioner visit prior to 
the index date the effect in those with lower eGFR was statisti-
cally different from those with better renal function. However, 
hypo- and hyperthyroidism were both not associated with gout 
(Table 5). Only patients without recorded eGFR prior to the 
index date were at slightly increased risk for incident gout in 
patients with hypo- or hyperthyroidism (Table 5).
Discussion
In this large population-based study using data from the UK-
based CPRD, we explored the risk of incident gout in asso-
ciation with previously diagnosed hypo- or hyperthyroidism 
and with their pharmacological therapy. While there was no 
clinically relevant overall association of hypo- or hyperthyroid-
ism and risk of gout, there was a small suggestion that current 
exposure to new onset hypothyroidism and its short-term treat-
ment may increase the risk compared with no hypothyroidism 
or hormone replacement therapy. Neither hyperthyroidism 
nor its therapy was associated with an increased risk of gout.
Our results in newly diagnosed and treated hypothyroid-
ism are consistent with previous studies that reported a high 
prevalence of hyperuricemia in patients with hypothyroid-
ism.11,12 We found no association between hyperthyroidism 
and gout despite available evidence from previous studies 
that hyperuricemia was present in patients with hyperthy-
roidism.10–12 The tendency toward a positive association 
between hypothyroidism and gout might be explained by 
the fact that thyroid hormones influence serum urate levels 
through regulation of GFR.13 Nevertheless, if this associa-
tion was only explained by renal impairment, patients with 
hypothyroidism whose kidney function was normal should 
not be at an increased risk of developing incident gout. 
Our analysis stratified by renal function, however, suggests 
Table 2 Comorbidities and comedication of patients with gout and matched control patients
Comorbidities and comedication Cases, n (%), N=68,159 Controls, n (%), N=68,159 OR crude (95% CI) OR adj (95% CI)
Comorbiditiesa
Hypertension 27,379 (40.2) 16,423 (24.1) 2.54 (2.47–2.61) 1.86 (1.80–1.92)
Diabetes mellitus 5,809 (8.5) 5,098 (7.5) 1.16 (1.11–1.21) 0.66 (0.63–0.70)
Dyslipidemia 9,622 (14.1) 6,364 (9.3) 1.70 (1.64–1.76) 1.14 (1.10–1.19)
Renal impairment 21,163 (31.1) 14,176 (20.8) 3.15 (3.03–3.27) 2.05 (1.96–2.14)
Congestive heart failure 4,667 (6.9) 1,364 (2.0) 4.06 (3.80–4.34) 3.37 (3.13–3.62)
Ischemic heart disease 10,309 (15.1) 6,572 (9.6) 1.80 (1.74–1.87) 1.23 (1.18–1.28)
Stroke/transient ischemic attack 4,092 (6.0) 2,981 (4.4) 1.43 (1.36–1.50) 1.13 (1.07–1.20)
Comedicationb 
Angiotensin-converting enzyme inhibitors 21,584 (31.7) 11,738 (17.2) 2.65 (2.57–2.73) 1.41 (1.36–1.47)
Angiotensin receptor blockers 6,266 (9.2) 3,192 (4.7) 2.20 (2.10–2.31) 1.11 (1.05–1.17)
Loop diuretics 11,366 (16.7) 4,664 (6.8) 3.35 (3.21–3.49) 2.29 (2.18–2.41)
Thiazide diuretics 17,672 (25.9) 9,879 (14.5) 2.37 (2.30–2.45) 1.63 (1.57–1.69)
Potassium-sparing diuretics 2,862 (4.2) 863 (1.3) 3.57 (3.29–3.86) 1.69 (1.54–1.85)
Beta-blockers 22,758 (33.4) 14,240 (20.9) 2.08 (2.02–2.14) 1.40 (1.35–1.44)
Calcium channel blockers 17,085 (25.1) 10,919 (16.0) 1.93 (1.88–1.99) 1.00 (0.96–1.04)
Nitrates 9,332 (13.7) 6,144 (9.0) 1.70 (1.64–1.76) 1.02 (0.97–1.07)
Statins 18,080 (26.5) 12,451 (18.3) 1.88 (1.83–1.94) 1.08 (1.04–1.13)
Notes: aAdjusted for body mass index category, smoking status, alcohol consumption, and concomitant diseases such as hypertension, renal impairment, congestive heart 
failure, and ischemic heart disease/myocardial infarction. bAdjusted for body mass index category, smoking status, alcohol consumption, and concomitant prescriptions 
of angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, loop diuretics, thiazide diuretics, potassium-sparing diuretics, beta-blockers, calcium channel 
blockers, nitrates, and statins.
Abbreviations: adj, adjusted; CI, confidence interval; OR, odds ratio
Table 3 Thyroid diseases of patients with gout and matched control patients stratified by timing
Thyroid disorders Cases (%), N=68,159 Controls, n (%), N=68,159 OR crude (95% CI) OR adja (95% CI)
Hypothyroidism
No 65,202 (95.7) 65,951 (96.8) 1 (Reference) 1 (Reference)
Yes 2,957 (4.3) 2,208 (3.2) 1.38 (1.30–1.46) 1.12 (1.05–1.20)
Hyperthyroidism
No 67,465 (99.0) 67,582 (99.2) 1 (Reference) 1 (Reference)
Yes 694 (1.0) 577 (0.9) 1.21 (1.08–1.35) 1.08 (0.95–1.22)
Notes: aAdjusted for body mass index category, smoking status, alcohol consumption, hypertension, renal impairment, congestive heart failure, and ischemic heart disease.
Abbreviations: adj, adjusted; CI, confidence interval; OR, odds ratioadj.
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that patients with hypothyroidism or hyperthyroidism who 
had no recorded renal impairment were still at a slightly 
increased risk of developing gout compared to patients 
without thyroid diseases and no recorded renal impairment. 
This observation might be explained by other effects of 
hypo- and hyperthyroidism on kidney function that can-
not be detected by measuring GFR, such as metabolic or 
cardiovascular effects.13 However, the influence of renal 
impairment within this subpopulation of patients without 
eGFR is beyond the scope of this study. Even if patients 
with recently diagnosed thyroid disease might have seen 
more often their physician, gouty arthritis is a very painful 
clinical condition and is most likely not diagnosed routinely 
or by chance. It is more likely that patients see their general 
practitioner because of acute joint pain than that they just 
wait for a follow-up consultation. It may be possible that 
patients who just started their treatment of hypothyroidism 
may be at greater risk of gout because a potential protective 
effect of thyroid hormone replacement therapy did not yet 
become active.
This large population-based study has several strengths. 
First, we were able to study a large number of cases with 
incident gout in a well-established and validated primary 
care database. Second, the diagnosis of gout has been vali-
dated,27 and similar case definitions for incident gout have 
been used by other authors.3,23–28 Third, we could study many 
cases with thyroid disorders and conduct various sensitivity 
analyses to address in-depth the potential role of thyroid 
hormone replacement or suppression therapy in the risk of 
incident gout. Fourth, unlike former studies,7–12 we could 
Table 4 Thyroid disease therapies of patients with gout and matched control patients stratified by timing and duration
Thyroid disorder 
therapies
Cases, n (%), N=68,159 Controls, n (%), N=68,159 OR crude (95% CI) OR adja (95% CI)
Treatment with thyroid HRT
Non-use 65,032 (95.4) 65,846 (96.6) 1 (Reference) 1 (Reference)
Overall use 3,127 (4.6) 2,313 (3.4) 1.40 (1.32–1.48) 1.15 (1.08–1.23)
Number of Rx
1–9 Rx 406 (0.6) 247 (0.4) 1.68 (1.43–1.97) 1.39 (1.16–1.66)
10–19 Rx 290 (0.4) 244 (0.4) 1.22 (1.03–1.45) 1.00 (0.82–1.21)
20–29 Rx 275 (0.4) 219 (0.3) 1.30 (1.09–1.55) 1.11 (0.91–1.37)
≥30 Rx 2,156 (3.2) 1,603 (2.4) 1.40 (1.30–1.49) 1.15 (1.06–1.24)
Current useb
Overall 2,964 (4.4) 2,146 (3.2) 1.43 (1.35–1.51) 1.17 (1.09–1.25)
1–9 Rx 301 (0.4) 154 (0.2) 1.99 (1.64–2.42) 1.54 (1.24–1.92)
10–19 Rx 260 (0.4) 219 (0.3) 1.21 (1.01–1.45) 0.98 (0.80–1.21)
20–29 Rx 265 (0.4) 206 (0.3) 1.33 (1.11–1.60) 1.15 (0.93–1.42)
≥30 Rx 2,138 (3.1) 1,567 (2.3) 1.41 (1.32–1.51) 1.16 (1.07–1.25)
Past usec
Overall 163 (0.2) 167 (0.3) 1.01 (0.82–1.26) 0.94 (0.73–1.20)
Treatment with thyroid HST
Nonuse 67,817 (99.5) 67,870 (99.6) 1 (Reference) 1 (Reference)
Overall use 342 (0.5) 289 (0.4) 1.19 (1.01–1.39) 0.94 (0.78–1.12)
Number of Rx
1–9 Rx 215 (0.3) 165 (0.2) 1.30 (1.06–1.60) 1.03 (0.81–1.31)
10–19 Rx 70 (0.1) 64 (0.1) 1.10 (0.78–1.54) 0.83 (0.56–1.22)
20–29 Rx 16 (0.0) 22 (0.0) 0.73 (0.38–1.39) 0.65 (0.30–1.39)
≥30 Rx 41 (0.1) 38 (0.1) 1.08 (0.69–1.68) 0.87 (0.53–1.45)
Current used
Overall 82 (0.1) 80 (0.1) 1.03 (0.75–1.40) 0.82 (0.57–1.17)
1–9 Rx 34 (0.1) 29 (0.0) 1.17 (0.71–1.92) 0.91 (0.50–1.63)
10–19 Rx 17 (0.0) 12 (0.0) 1.42 (0.68–2.98) 0.90 (0.41–2.01)
20–29 Rx 9 (0.0) 10 (0.0) 0.90 (0.37–2.22) 1.16 (0.43–3.17)
≥30 Rx 22 (0.0) 29 (0.0) 0.76 (0.44–1.32) 0.59 (0.31–1.12)
Past usee
Overall 260 (0.4) 209 (0.3) 1.25 (1.04–1.50) 0.98 (0.79–1.22)
Notes: Current use: last prescription within 180 days preceding (excluding) the index date. aAdjusted for body mass index category, smoking status, alcohol consumption, 
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, loop diuretics, thiazide diuretics, potassium-sparing diuretics, beta-blockers, calcium channel 
blockers, nitrates, and statins. bLast prescription of thyroid HRT recorded <180 days prior to (excluding) the index date. cLast prescription of thyroid HRT recorded 
≥180 days prior to (excluding) the index date. dLast prescription of thyroid HST recorded <180 days prior to (excluding) the index date. eLast prescription of thyroid HST 
recorded ≥180 days prior to (excluding) the index date.
Abbreviations: adj, adjusted; CI, confidence interval; HRT, hormone replacement therapy; HST, hormone suppression therapy; OR, odds ratio; Rx: prescriptions.
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adjust our analyses for important potential confounders such 
as age and sex, by matching, and important lifestyle factors, 
comorbidities, or concomitant drug therapy, by including 
them in the multivariable regression models. Fifth, recall 
bias was not an issue in this study as information on diseases 
and drug exposure was prospectively entered in the CPRD 
in the absence of any study hypothesis. Finally, exclusion of 
all patients with <3 years of recorded history in the database 
prior to the index date reduced the likelihood of including 
prevalent rather than incident gout patients.
Some limitations of our study must be acknowledged. 
Although the diagnosis of gout has been validated and found 
to be well documented in the CPRD,27 there may still be some 
outcome misclassification. Gout diagnoses are often made 
based on clinical presentation and are rarely confirmed in 
routine clinical practice by analysis of aspirated joint fluid 
for evidence of urate crystals. To minimize misclassifica-
tion, we only included gout patients who had no differential 
diagnoses of gout such as osteoarthritis, septic arthritis, 
hemochromatosis, and rheumatoid arthritis recorded at 
any time within their patient record. We were not able to 
disentangle effects of the underlying thyroid disorder from 
effects of thyroid hormone therapy on the risk of gout because 
hypo- and hyperthyroidism are treated with thyroid hormone 
replacement or suppression therapy. A further limitation was 
that GFR measurements were not available for all patients 
in the study. This is a common problem when dealing with 
laboratory values or biomarkers that are an important part 
of diagnostic assessments. Residual confounding by indica-
tion by CKD and congestive heart failure which are causally 
linked to development of hyperuricemia, cannot be excluded 
in the present study despite every effort to minimize such 
a bias. We adjusted for use of drugs indicated for treatment 
of these comorbidities, and we stratified our analyses by 
the most important chronic comorbidities, namely arterial 
hypertension, congestive heart failure, and renal impairment.
We did not adjust for all potential risk factors for gout, 
since, for example, dietary habits or physical activities2,31 are 
not routinely recorded in the CPRD. However, we adjusted for 
BMI, a factor that is related to physical activity and dietary 
habits. Furthermore, we were not able to take race/ethnicity 
into account when calculating eGFR with the CKD-EPI for-
mula because ethnicity information is not consistently avail-
able in the CPRD. However, since most individuals  living in 
Table 5 Thyroid diseases of patients with gout and matched control patients stratified by GFR
Glomerular filtration rate Cases, n (%), N=68,159 Controls, n (%), N=68,159 OR crude (95% CI) OR adj* (95% CI)
Value of last eGFR prior to the index date
Overall population
No value 41,340 (60.7) 48,440 (71.1) 0.38 (0.36–0.39) 0.66 (0.63–0.69)
<30 mL/min 1,119 (1.6) 194 (0.3) 10.99 (9.18–13.16) 7.76 (6.41–9.40)
30–60 mL/min 5,306 (7.8) 2,972 (4.4) 2.90 (2.69–3.12) 2.43 (2.24–2.63)
60–90 mL/min 20,394 (29.9) 16,553 (24.3) 1 (Reference) 1 (Reference)
Hypothyroidism
Hypothyroidism, no value 946 (1.4) 850 (1.3) 1.39 (1.26 – 1.53) 1.25 (1.09–1.35)
No hypothyroidism, no value 40,394 (59.3) 47,590 (69.8) 1 (Reference) 1 (Reference)
Hypothyroidism, <30 mL/min 184 (0.3) 34 (0.1) 0.85 (0.55–1.31) 0.79 (0.50–1.24)
No hypothyroidism, <30 mL/min 935 (1.4) 160 (0.2) 1 (Reference) 1 (Reference)
Hypothyroidism, 30–59 mL/min 735 (1.1) 384 (0.6) 1.14 (0.99–1.32) 1.03 (0.88–1.21)
No hypothyroidism, 30–59 mL/min 4,571 (6.7) 2,588 (3.8) 1 (Reference) 1 (Reference)
Hypothyroidism, 60–90 mL/min 1,092 (1.6) 940 (1.4) 1.07 (0.97–1.18) 1.01 (0.90–1.12)
No hypothyroidism, 60–90 mL/min 19,302 (28.3) 15,613 (22.9) 1 (Reference) 1 (Reference)
Hyperthyroidism
Hyperthyroidism, no value 946 (0.4) 283 (0.4) 1.17 (0.98–1.39) 1.25 (1.03–1.52)
No hyperthyroidism, no value 40,394 (60.3) 48,157 (70.6) 1 (Reference) 1 (Reference)
Hyperthyroidism, <30 mL/min 184 (0.1) 5 (0.01) 1.11 (0.41–3.01) 1.02 (0.36–2.93)
No hyperthyroidism, <30 mL/min 1,087 (1.6) 189 (0.3) 1 (Reference) 1 (Reference)
Hyperthyroidism, 30–59 mL/min 144 (0.2) 82 (0.1) 0.98 (0.72–1.32) 0.88 (0.63 – 1.23)
No hyperthyroidism, 30–59 mL/min 5,162 (7.6) 2,890 (4.2) 1 (Reference) 1 (Reference)
Hyperthyroidism, 60–90 mL/min 259 (0.4) 207 (0.3) 1.09 (0.90–1.33) 0.94 (0.75–1.17)
No hyperthyroidism, 60–90 mL/min 20,135 (29.5) 16,346 (24.0) 1 (Reference) 1 (Reference)
Notes: The reference is in each category the same kidney function category without the respective thyroid disease, eg, hypothyroidism <30 mL/min compared to no 
hypothyroidism <30 mL/min. *Adjusted for body mass index category, smoking status, alcohol consumption, hypertension, renal failure, congestive heart failure, and ischemic 
heart disease.
Abbreviations: adj, adjusted; CI, confidence interval; eGFR, estimated glomerular filtration rate; OR, odds ratio.
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the UK are Caucasian,32 our results are representative of large 
portion of the UK population. Finally, we could not address 
potential confounding by socioeconomic status; however, we 
partially controlled for this potential confounder by matching 
cases and controls from the same general practice, since it 
is likely that patients from the same neighborhood see the 
same general practitioner.
Conclusion
This large observational study does not provide evidence that 
hypothyroidism, irrespective of its treatment, and hyperthy-
roidism, are associated with a clinically relevant increased 
risk of developing incident gout. There may be a small 
increased risk of gout in patients with newly diagnosed and 
treated hypothyroidism.
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Supplementary materials
Table S1 Sensitivity analysis 1: patients without hypertension, congestive heart failure, or renal impairment prior to the index date
Thyroid disorders Cases, n (%), N=33,191 Controls, n (%), N=45,363 OR crude (95% CI) OR adj* (95% CI)
Hypothyroidism
No 32,604 (98.2) 44,597 (98.3) 1 (Reference) 1 (Reference)
Yes 587 (1.8) 766 (1.7) 1.29 (1.12–1.50) 1.12 (0.95–1.31)
Current diagnosis 67 (0.2) 69 (0.2) 1.40 (0.91–2.17) 1.13 (0.71–1.82)
Past diagnosis 520 (1.6) 697 (1.5) 1.28 (1.10–1.50) 1.12 (0.94–1.32)
Hyperthyroidism
No 33,028 (99.5) 45,116 (99.5) 1 (Reference) 1 (Reference)
Yes 163 (0.5) 247 (0.5) 1.25 (0.96–1.63) 0.73 (0.58–0.91)
Current diagnosis 8 (0.0) 18 (0.0) 0.65 (0.25–1.67) 0.70 (0.24–2.06)
Past diagnosis 155 (0.5) 229 (0.5) 1.32 (1.00–1.75) 1.35 (1.00–1.83)
Notes: Current diagnosis: last diagnosis within 180 days prior to (excluding) index date. *Adjusted for body mass index category, smoking status, alcohol consumption, and 
ischemic heart disease.
Abbreviations: adj, adjusted; CI, confidence interval; OR, odds ratio.
Table S2 Sensitivity analysis 2: stratified by hypertension, congestive heart failure, and renal impairment
 Stratification variable Cases, n (%), N=68,159 Controls, n (%), N=68,159 OR crude (95% CI) OR adj* (95% CI)
Hypertension
Hypothyroidism
Without hypertension
No 39,564 (58.1) 50,471 (74.1) 1 (Reference) 1 (Reference)
Yes 1,216 (1.8) 1,265 (1.9) 1.46 (1.34–1.59) 1.15 (1.05–1.26)
With hypertension
No 25,638 (37.6) 15,480 (22.7) 1 (Reference) 1 (Reference)
Yes 1,741 (2.6) 943 (1.4) 1.24 (1.14–1.35) 1.10 (1.00–1.20)
Hyperthyroidism 
Without hypertension
No 40,484 (59.4) 51,390 (75.4) 1 (Reference) 1 (Reference)
Yes 296 (0.4) 346 (0.5) 1.25 (1.07–1.47) 1.14 (0.96–1.36)
With hypertension
No 26,981 (39.6) 16,192 (23.8) 1 (Reference) 1 (Reference)
Yes 398 (0.6) 231 (0.3) 1.07 (0.91–1.27) 1.01 (0.84–1.21)
Congestive heart failure
Hypothyroidism 
Without congestive heart failure
No 60,992 (89.5) 64,698 (94.9) 1 (Reference) 1 (Reference)
Yes 2,500 (3.7) 2,097 (3.1) 1.32 (1.25–1.41) 1.13 (1.05–1.21)
With congestive heart failure
No 4,210 (6.2) 1,253 (1.8) 1 (Reference) 1 (Reference)
Yes 457 (0.7) 111 (0.2) 1.19 (0.95–1.48) 1.10 (0.87–1.40)
Hyperthyroidism 
Without congestive heart failure
No 62,948 (92.4) 66,260 (97.2) 1 (Reference) 1 (Reference)
Yes 544 (0.8) 535 (0.8) 1.11 (0.98–1.26) 1.09 (0.95–1.25)
With congestive heart failure
No 4,517 (6.6) 1,322 (1.9) 1 (Reference) 1 (Reference)
Yes 150 (0.2) 42 (0.1) 0.98 (0.69–1.39) 0.97 (0.66–1.41)
Renal impairment
Hypothyroidism 
Without renal impairment
No 45,839 (67.3) 52,886 (77.6) 1 (Reference) 1 (Reference)
Yes 1,157 (1.7) 1,097 (1.6) 1.28 (1.18–1.40) 1.14 (1.04–1.25)
With renal impairment
No 19,363 (28.4) 13,065 (19.2) 1 (Reference) 1 (Reference)
Yes 1,800 (2.6) 1,111 (1.6) 1.15 (1.06–1.25) 1.11 (1.02–1.22)
(Continued)
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
15
2.
11
2.
13
9 
on
 2
5-
Ju
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
214
Bruderer et al
Table S2 (Continued)
 Cases, n (%), N=68,159 Controls, n (%), N=68,159 OR crude (95% CI) OR adj* (95% CI)
Hyperthyroidism 
Without renal impairment
No 46,684 (68.5) 53,635 (78.7) 1 (Reference) 1 (Reference)
Yes 312 (0.5) 348 (0.5) 1.08 (0.92–1.26) 1.13 (0.95–1.34)
With renal impairment
No 20,781 (30.5) 13,947 (20.5) 1 (Reference) 1 (Reference)
Yes 382 (0.6) 229 (0.3) 1.13 (0.95–1.35) 1.02 (0.84–1.23)
Notes: *Adjusted for body mass index category, smoking status, alcohol consumption, hypertension, and renal failure.
Abbreviations: adj, adjusted; CI, confidence interval; OR, odds ratio.
Table S3 Sensitivity analysis 3: patients with treated gout compared with matched controls
Thyroid disorders Cases, n (%), N=45,466 Controls, n (%), N=45,466 OR crude (95% CI) OR adj* (95% CI)
Hypothyroidism
No 43,478 (95.6) 43,987 (96.8) 1 (Reference) 1 (Reference)
Yes 1,988 (4.4) 1,479 (3.3) 1.39 (1.29–1.49) 1.10 (1.02–1.20)
Current diagnosis 165 (0.4) 110 (0.2) 1.54 (1.21–1.96) 1.34 (1.01–1.77)
Past diagnosis 1,823 (4.0) 1,369 (3.0) 1.37 (1.28–1.48) 1.09 (1.00–1.18)
Hyperthyroidism
No 44,978 (98.9) 45,063 (99.1) 1 (Reference) 1 (Reference)
Yes 488 (1.1) 403 (0.9) 1.21 (1.06–1.39) 1.03 (0.88–1.21)
Current diagnosis 31 (0.1) 24 (0.1) 1.29 (0.76–2.20) 0.92 (0.49–1.70)
Past diagnosis 457 (1.0) 379 (0.8) 1.21 (1.05–1.39) 1.04 (0.88–1.22)
Notes: Current diagnosis: last diagnosis within 180 days prior to (excluding) index date. *Adjusted for body mass index category, smoking status, alcohol consumption, 
hypertension, renal failure, congestive heart failure, and ischemic heart disease.
Abbreviations: adj, adjusted; CI, confidence interval; OR, odds ratio.
Table S4 Test for effect modification analysis 1: stratification by sex
Stratification variable Cases, n (%), N=68,159 Controls, n (%), N=68,159 OR crude (95% CI) OR adj* (95% CI)
Male population 53,736 (100) 53,736 (100)
Hypothyroidism
No 52,547 (97.8) 52,870 (98.4) 1 (Reference) 1 (Reference)
Yes 1,189 (2.2) 866 (1.6) 1.39 (1.27–1.52) 1.15 (1.04–1.28)
Current diagnosis 138 (0.3) 81 (0.2) 1.72 (1.31–2.26) 1.33 (0.98–1.81)
Past diagnosis 1,051 (2.0) 785 (1.5) 1.35 (1.23–1.49) 1.14 (1.02–1.26)
Hyperthyroidism
No 53,414 (99.4) 53,502 (99.6) 1 (Reference) 1 (Reference)
Yes 322 (0.6) 234 (0.4) 1.38 (1.16–1.63) 1.16 (0.96–1.41)
Current diagnosis 20 (0.0) 15 (0.0) 1.33 (0.68–2.60) 1.13 (0.53–2.38)
Past diagnosis 302 (0.6) 219 (0.4) 1.38 (1.16–1.64) 1.17 (0.95–1.42)
Female population 14,423 (100) 14,423 (100)
Hypothyroidism
No 12,655 (87.7) 13,081 (90.7) 1 (Reference) 1 (Reference)
Yes 1,768 (12.3) 1,342 (9.3) 1.37 (1.27–1.48) 1.07 (0.98–1.17)
Current diagnosis 113 (0.8) 83 (0.6) 1.41 (1.06–1.87) 1.28 (0.92–1.79)
Past diagnosis 1,655 (11.5) 1,259 (8.7) 1.37 (1.27–1.48) 1.06 (0.97–1.16)
Hyperthyroidism
No 14,051 (97.4) 14,080 (97.6) 1 (Reference) 1 (Reference)
Yes 372 (2.6) 343 (2.4) 1.09 (0.94–1.26) 0.98 (0.82–1.17)
Current diagnosis 20 (0.1) 18 (0.1) 1.11 (0.59–2.11) 0.89 (0.42–1.89)
Past diagnosis 352 (2.4) 325 (2.3) 1.09 (0.93–1.27) 0.98 (0.82–1.18)
Notes: Current diagnosis: last diagnosis within 180 days prior to (excluding) index date. *Adjusted for body mass index category, smoking status, alcohol consumption, 
hypertension, renal failure, congestive heart failure, and ischemic heart disease.
Abbreviations: adj, adjusted; CI, confidence interval; OR, odds ratio.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
15
2.
11
2.
13
9 
on
 2
5-
Ju
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk and safety of medical interventions, epidemiol-
ogy and biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies and economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Dovepress
215
Thyroid disorders and gout
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
15
2.
11
2.
13
9 
on
 2
5-
Ju
n-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
